Medicaid Outpatient Prescription Drugs: Second Quarter 2008 Federal Upper Limits for Reimbursement Compared with Average Retail Pharmacy Acquisition Costs
DIANE Publishing, 2010 - 35 pages
Medicaid spent $15 billion on outpatient prescription drugs (PD) in FY 2007. Instead of directly purchasing PD, state Medicaid programs reimburse pharmacies for dispensing them to Medicaid beneficiaries. For certain PD, state Medicaid programs may only receive fed. matching funds for reimburse. up to a max. amount known as a fed. upper limit (FUL). The Deficit Reduction Act of 2005 changed the methodology for calculating FULs. This report found that if AMP-based FULs had been in place in the 2nd qtr. of 2008, they would have been lower than avg. retail pharmacy costs for most of the drugs in the sample and in the nat. aggregate. However, 64 drugs had at least one therapeutically equivalent version with acquisition costs below the FUL. Illus.
What people are saying - Write a review
We haven't found any reviews in the usual places.
100mg/5ml Suspension 10mg Tablet High 83 drugs account for rebates Acetaminophen acquisition cost data aggregate Alprazolam Amlodipine Amoxicillin AMP data average pharmacy acquisition average retail pharmacy Azithromycin based FULs Bupropion Cefdinir clavulanic acid Clonazepam costs for multiple-source data from CMS data sources discounts and rebates discounts that pharmacies drug manufacturers drug’s Medicaid utilization drugs that account Federal Upper Limits Fentanyl final rule FUL data Gabapentin High expenditure 0.0 high-utilization drugs hydrochloride 10mg hydrochloride 50mg Tablet hydrocodone Ibuprofen identify any data IMS Health Lorazepam median AMP-based FULs Medicaid programs multiple-source drugs multiple-source outpatient prescription obtained from IMS Ofloxacin outpatient prescription drugs Oxcarbazepine pharmacies may receive pharmacy acquisition costs published prices quarter of 2008 Ranitidine rebates and discounts receive from wholesalers retail pharmacy acquisition Sertraline sources of acquisition Suspension High utilization Tablet High expenditure Tablet High utilization therapeutically equivalent versions utilization and FUL utilization and high utilization data wholesalers or manufacturers